Autologous monocyte-derived DC vaccination combined with cisplatin in stage III and IV melanoma patients: a prospective, randomized phase 2 trial

Steve Boudewijns,Martine Bloemendal,Nienke de Haas,Harm Westdorp,Kalijn F. Bol,Gerty Schreibelt,Erik H.J.G. Aarntzen,W. Joost Lesterhuis,Mark A.J. Gorris,A. J. Croockewit,Lieke L. van der Woude,Michelle M. van Rossum,Marieke E. B. Welzen,Anna L. de Goede,Stanleyson V. Hato,Winette T. A. van der Graaf,Cornelis J. A. Punt,Rutger H. T. Koornstra,Winald R. Gerritsen,Carl G. Figdor,I. Jolanda M. de Vries

Autologous monocyte-derived DC vaccination combined with cisplatin in stage III and IV melanoma patients: a prospective, randomized phase 2 trial

2020

Background Autologous dendritic cell (DC) vaccines can induce tumor-specific T cells, but their effect can be counteracted by immunosuppressive mechanisms. Cisplatin has shown immunomodulatory effects in vivo which may enhance efficacy of DC vaccination.

Keywords:

Immunotherapy
Cisplatin
In vivo
Monocyte
Melanoma
Dendritic cell
Immunology
Vaccination
Biology
Combination therapy
Internal medicine
Phases of clinical research
Oncology
Adverse effect
CD8
T cell

Correction
Source
Cite
Save
Machine Reading By IdeaReader

References

Citations